Nurix Therapeutics share price logo

Nurix Therapeutics

NASDAQ: NRIX

Mid Cap

$22.99

-0.35

(-1.50%)

as on

Nurix Therapeutics Stock Performance

as on October 5, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $22.85
    $23.72
    downward going graph

    0.61%

    Downside

    3.18%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $9.00
    $28.23
    downward going graph

    60.85%

    Downside

    22.79%

    Upside

    downward going graph

Nurix Therapeutics share price movements today

Previous Close
$23.34
Open
$23.49
Volume
447.1K
Market Cap
$2.4B
Day's Low - High
$22.85 - $23.72
52 Week Low - High
$9.00 - $28.23

Nurix Therapeutics Historical Returns

1 Month Return
-12.05 %
3 Month Return
-4.09 %
1 Year Return
+ 145.1 %
3 Year Return
+ 234.16 %
5 Year Return
-24.3 %

Nurix Therapeutics Stock Fundamentals & Key Indicators

Check Nurix Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4B

EPS (TTM)

-3.45

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-6.66

Industry PE ratio

-11.70

PEG Ratio

0.25

EBITDA

-319.7M

Revenue (TTM)

36.8M

Profit Margin

-165.51%

Return On Equity TTM

-76.09%

Nurix Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Nurix Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Nurix Therapeutics image
Nurix Therapeutics
StrongBuy$2.4B-24.30%-6.66-165.51%0.00%
Revolution Medicines image
Revolution Medicines
StrongBuy$44.3B637.21%-23.320.00%0.00%
Moderna image
Moderna
Neutral$75.9B-42.79%-23.81-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$127.9B185.14%29.1486.04%0.00%
Regeneron image
Regeneron
Buy$75.7B33.45%17.5584.86%0.50%

Stock Returns calculator for Nurix Therapeutics Stock including INR - Dollar returns

The Nurix Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Nurix Therapeutics investment value today

Current value as on today

₹2,66,033

Returns

₹1,66,033

(+166.03%)

Returns from Nurix Therapeutics Stock

₹1,45,096 (+145.1%)

Dollar Impact

₹20,937 (+20.94%)

Analyst Recommendation on Nurix Therapeutics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for Nurix Therapeutics. Average target price of $33.93

Nurix Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Nurix Therapeutics.

What analysts predicted

32.24%UPSIDE

Target Price

$33.93

Current Price

$22.99

Analyzed by

8 Analysts

High

$40

Target

$33.93

Low

$25

Nurix Therapeutics target price $33.93, a slight upside of 32.24% compared to current price of $22.99. According to 8 analysts rating.

Indian Investors' Interest in Nurix Therapeutics Stock

Search interest for Nurix Therapeutics Stock has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-39% versus previous 30 day period

Nurix Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Feb 2024
May 2024
Aug 2024
Nov 2024
Feb 2025
May 2025
Aug 2025
Nov 2025
Feb 2026
May 2026
Total Revenue
16
12
12
13
18
44
7
13
6
9
Gross Profit
-33
-36
-42
-53
-51
-34
2
8
-77
5
Operating Income
-45
-48
-54
-64
-62
-48
-91
-83
-92
-94
EBITDA
-39
-42
-46
-57
-54
-40
-81
-68
-83
-85
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
2
2
2
1
2
2
5
9
3
3
Income Before Tax
-41
-44
-48
-58
-56
-42
-86
-78
-87
-89
Income Tax Expense
0
0
0
0
-
0
-
-
-
0
Net Income
-41
-44
-48
-58
-56
-43
-86
-78
-87
-89
Net Profit Margin
-201.51%
-304.58%
-340.75%
-406.05%
-277.52%
-77.27%
36.66%
65.89%
-1245.76%
57.43%

Nurix Therapeutics Annual Profit & Loss

All numbers in Millions USD

Nov 2018
Nov 2019
Nov 2020
Nov 2021
Nov 2022
Nov 2023
Nov 2024
Nov 2025
Total Revenue
37
31
17
29
38
76
54
83
Gross Profit
-3
-13
-48
-86
-145
-112
-167
65
Operating Income
-9
-22
-64
-117
-183
-155
-213
-285
EBITDA
-6
-19
-62
-115
-176
-137
-185
-244
Interest Expense
-
-
-
-
-
-
-
-
Depreciation
2
2
2
1
4
6
8
18
Income Before Tax
-8
-21
-63
-117
-180
-143
-193
-263
Income Tax Expense
0
0
-20
0
-
-
0
0
Net Income
-9
-21
-43
-117
-180
-143
-193
-264
Net Profit Margin
-8.18%
-44.71%
-273.14%
-291.37%
-377.64%
-145.69%
-306.30%
77.55%

Nurix Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Feb 2024
May 2024
Aug 2024
Nov 2024
Feb 2025
May 2025
Aug 2025
Nov 2025
Feb 2026
May 2026
Net Income
-41
-44
-48
-58
-56
-43
-86
-78
-87
-89
Operating Cash Flow
-41
-39
-42
-48
-61
-63
-57
-67
-71
-96
Investing Cash Flow
35
-131
-21
-140
25
71
50
0
-123
92
Financing Cash Flow
1
237
45
200
1
0
1
236
19
0
Change in Cash
-4
66
-17
10
-34
8
-5
168
-175
-3

Nurix Therapeutics Annual Cash Flow

All numbers in Millions USD

Nov 2018
Nov 2019
Nov 2020
Nov 2021
Nov 2022
Nov 2023
Nov 2024
Nov 2025
Net Income
-9
-21
-43
-117
-180
-143
-193
-264
Operating Cash Flow
-31
0
0
-84
-159
-81
-172
-249
Investing Cash Flow
39
8
-254
-108
27
68
-257
147
Financing Cash Flow
0
0
339
153
117
3
485
238
Change in Cash
8
9
84
-38
-15
-9
55
137

Global Institutional Holdings in Nurix Therapeutics

Check out the Institutions with significant holdings in Nurix Therapeutics.

Funds
Holdings
Vanguard
5.09%
iShares
4.83%
Felix Baker
4.49%
Joseph Edelman
4.16%
VANGUARD INDEX FUNDS
4.15%
See all

Nurix Therapeutics News & Key Events

  • img

    Today's Timeline - 29 September

    Tue, 04:30 PM

    -

    Nurix Therapeutics achieves $7M milestone under Pfizer collaboration, totaling $82M received to date.

Insights on Nurix Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NRIX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, NRIX stock has moved up by 48.2%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 6.25M → 9.04M (in $), with an average increase of 30.9% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 421.8%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -78.22M → -89.53M (in $), with an average decrease of 7.1% per quarter

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
OrganisationNurix Therapeutics
Headquarters1600 Sierra Point Parkway, Brisbane, CA, 94005, US
IndustryBiotechnology
CEOArthur T. Sands

Key Management of Nurix Therapeutics

Name

Title

Mr. Johannes Van Houte

Chief Financial Officer

Dr. Arthur Weiss M.D., Ph.D.

Founder & Member of Scientific Advisory Board

Rita Kwong

Senior Accounting Manager

Dr. Pasit Phiasivongsa Ph.D.

Chief Technical Officer

Dr. Jason Kantor Ph.D.

Chief Business Officer

Dr. Arthur T. Sands M.D., Ph.D.

CEO, President & Director

Dr. Christine Ring J.D., Ph.D.

Chief Legal Officer, Secretary & Chief Compliance Officer

Dr. John Kuriyan Ph.D.

Founder & Member of Scientific Advisory Board

Mr. Wesley Burwell

Chief Human Resources Officer

Dr. Gwenn M. Hansen Ph.D.

Chief Scientific Officer

FAQs

What is Nurix Therapeutics share price today?

Nurix Therapeutics share price today is $22.99 as on at the close of the market. Nurix Therapeutics share today touched a day high of $23.72 and a low of $22.85.

What is the 52 week high and 52 week low for Nurix Therapeutics share?

Nurix Therapeutics share touched a 52 week high of $28.23 on and a 52 week low of $9.00 on . Nurix Therapeutics stock price today i.e. is closed at $22.99,which is 18.56% down from its 52 week high and 155.44% up from its 52 week low.

What is Nurix Therapeutics's market capitalisation today?

Nurix Therapeutics market capitalisation is $0.00T as on .

How to invest in Nurix Therapeutics Stock (NRIX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Nurix Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Nurix Therapeutics Stock (NRIX) from India?

Indian investors can start investing in Nurix Therapeutics (NRIX) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Nurix Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Nurix Therapeutics share’s latest price of $22.99 as on October 5, 2026 at 8:45 am IST, you will get 0.4350 shares of Nurix Therapeutics. Learn more about fractional shares .

What are the returns that Nurix Therapeutics has given to Indian investors in the last 5 years?

Nurix Therapeutics stock has given -24.3% share price returns and 29.14% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?